Top

Clinical and Translational Oncology

Published in:

01-09-2014 | Research Article

Snail1 correlates with patient outcomes in E-cadherin-preserved gastroesophageal junction adenocarcinoma

Authors: H. Dong, L. Xie, C. Tang, S. Chen, Q. Liu, Q. Zhang, W. Zheng, Z. Zheng, H. Zhang

Published in: Clinical and Translational Oncology | Issue 9/2014

Abstract

Purpose

The poor prognosis of gastroesophageal junction (GEJ) adenocarcinoma is largely associated with metastasis. We here report the first study to investigate the expression of epithelial-mesenchymal transition (EMT) markers Snail1 and E-cadherin in GEJ adenocarcinoma.

Methods

Snail1 and E-cadherin were detected by immunohistochemistry in a cohort of 128 patients with surgically resected GEJ adenocarcinoma. We assessed the pathologic and prognostic relevance in all patients and within clinically different preserved E-cadherin and reduced E-cadherin-expressing sub-groups.

Results

Immunoreactivity for Snail1 and E-cadherin was positive in 68 and 43 % of tumors, respectively. Snail1-positive tumors had more frequent lymph node metastasis and advanced tumor stage. E-cadherin expression was highly associated with histological differentiation, tumor size, advanced stage, presence of lymph node metastasis and distant metastasis. Patients with positive E-cadherin expression or negative Snail1 expression had significantly favorable overall survival rate. In E-cadherin-preserved tumors, the expression of Snail1 was related to lymph node metastasis, advanced stage and poor patient outcome. However, Snail1 expression had no statistically significant relationship with clinicopathologic parameters or prognosis in the reduced E-cadherin-expressing sub-group. Multivariate survival analysis identified that tumor stage [hazard ratio (HR) 2.440; 95 % confidence interval (CI) 1.216–4.896; P = 0.012], lymph node metastasis (HR 2.404; 95 % CI 1.188–4.867; P = 0.015) and gender (HR 3.244; 95 % CI 1.568–6.714; P = 0.002) were independent prognostic markers for overall survival.

Conclusions

Snail1 may act more critically in E-cadherin-positive tumors. Evaluation of Snail1 and E-cadherin in GEJ adenocarcinoma may help in assessing malignant properties and stratifying patients.

Available only for authorised users

Moehler M, Lyros O, Gockel I, Galle PR, Lang H. Multidisciplinary management of gastric and gastroesophageal cancers. WJG. 2008;14(24):3773–80.PubMedCentralPubMedCrossRef

Menges M, Hoehler T. Current strategies in systemic treatment of gastric cancer and cancer of the gastroesophageal junction. J Cancer Res Clin Oncol. 2009;135(1):29–38. doi:10.1007/s00432-008-0425-z.PubMedCrossRef

Bain GH, Petty RD. Predicting response to treatment in gastroesophageal junction adenocarcinomas: combining clinical, imaging, and molecular biomarkers. Oncologist. 2010;15(3):270–84. doi:10.1634/theoncologist.2009-0293.PubMedCentralPubMedCrossRef

Nakamura M, Iwahashi M, Nakamori M, Naka T, Ojima T, Iida T, et al. Lower mediastinal lymph node metastasis is an independent survival factor of Siewert type II and III adenocarcinomas in the gastroesophageal junction. Am Surg. 2012;78(5):567–73.PubMed

Maeda H, Okabayashi T, Nishimori I, Sugimoto T, Namikawa T, Dabanaka K, et al. Clinicopathologic features of adenocarcinoma at the gastric cardia: is it different from distal cancer of the stomach? J Am Coll Surg. 2008;206(2):306–10. doi:10.1016/j.jamcollsurg.2007.06.306.PubMedCrossRef

Pedrazzani C, de Manzoni G, Marrelli D, Giacopuzzi S, Corso G, Minicozzi AM, et al. Lymph node involvement in advanced gastroesophageal junction adenocarcinoma. J Thorac Cardiovasc Surg. 2007;134(2):378–85. doi:10.1016/j.jtcvs.2007.03.034.PubMedCrossRef

Lagarde SM, ten Kate FJ, de Boer DJ, Busch OR, Obertop H, van Lanschot JJ. Extracapsular lymph node involvement in node-positive patients with adenocarcinoma of the distal esophagus or gastroesophageal junction. Am J Surg Pathol. 2006;30(2):171–6.PubMedCrossRef

Gu Y, Swisher SG, Ajani JA, Correa AM, Hofstetter WL, Liao Z, et al. The number of lymph nodes with metastasis predicts survival in patients with esophageal or esophagogastric junction adenocarcinoma who receive preoperative chemoradiation. Cancer. 2006;106(5):1017–25. doi:10.1002/cncr.21693.PubMedCrossRef

Matsumoto M, Natsugoe S, Nakashima S, Sakamoto F, Okumura H, Sakita H, et al. Clinical significance of lymph node micrometastasis of pN0 esophageal squamous cell carcinoma. Cancer Lett. 2000;153(1–2):189–97.PubMedCrossRef

10.

Yang Z, Zhang H, Kumar R. Regulation of E-cadherin. In: Breast Cancer Online. Cambridge University Press 2005. http://journals.cambridge.org/article_S1470903105003159.

11.

Blanco MJ, Moreno-Bueno G, Sarrio D, Locascio A, Cano A, Palacios J, et al. Correlation of Snail expression with histological grade and lymph node status in breast carcinomas. Oncogene. 2002;21(20):3241–6. doi:10.1038/sj.onc.1205416.PubMedCrossRef

12.

Sobin LH, Compton CC. TNM seventh edition: what’s new, what’s changed: communication from the International Union Against Cancer and the American Joint Committee on Cancer. Cancer. 2010;116(22):5336–9. doi:10.1002/cncr.25537.PubMedCrossRef

13.

Zhang H, Stephens LC, Kumar R. Metastasis tumor antigen family proteins during breast cancer progression and metastasis in a reliable mouse model for human breast cancer. Clin Cancer Res. 2006;12(5):1479–86. doi:10.1158/1078-0432.CCR-05-1519.PubMedCrossRef

14.

Natsugoe S, Uchikado Y, Okumura H, Matsumoto M, Setoyama T, Tamotsu K, et al. Snail plays a key role in E-cadherin-preserved esophageal squamous cell carcinoma. Oncol Rep. 2007;17(3):517–23.PubMed

15.

Uchikado Y, Okumura H, Ishigami S, Setoyama T, Matsumoto M, Owaki T, et al. Increased Slug and decreased E-cadherin expression is related to poor prognosis in patients with gastric cancer. Gastric cancer: Off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc. 2011;14(1):41–9. doi:10.1007/s10120-011-0004-x.CrossRef

16.

Rosivatz E, Becker I, Specht K, Fricke E, Luber B, Busch R, et al. Differential expression of the epithelial-mesenchymal transition regulators snail, SIP1, and twist in gastric cancer. Am J Pathol. 2002;161(5):1881–91. doi:10.1016/S0002-9440(10)64464-1.PubMedCentralPubMedCrossRef

17.

He H, Chen W, Wang X, Wang C, Liu F, Shen Z, et al. Snail is an independent prognostic predictor for progression and patient survival of gastric cancer. Cancer Sci. 2012;103(7):1296–303. doi:10.1111/j.1349-7006.2012.02295.x.PubMedCrossRef

18.

Stanculescu D, Margaritescu C, Stepan A, Mitrut AO. E-cadherin in gastric carcinomas related to histological prognostic parameters. Rom J Morphol Embryology = Revue Roumaine de Morphologie et Embryologie. 2011;52(3 Suppl):1107–12.

19.

Chan AO. E-cadherin in gastric cancer. World J Gastroenterol: WJG. 2006;12(2):199–203.PubMedCentralPubMed

20.

Wang ZS, Shen Y, Li X, Zhou CZ, Wen YG, Jin YB, et al. Significance and prognostic value of Gli-1 and Snail/E-cadherin expression in progressive gastric cancer. Tumour Biol: J Int Soc Oncodevelopmental Biol Med. 2013;. doi:10.1007/s13277-013-1185-1.

21.

Rosivatz E, Becker KF, Kremmer E, Schott C, Blechschmidt K, Hofler H, et al. Expression and nuclear localization of Snail, an E-cadherin repressor, in adenocarcinomas of the upper gastrointestinal tract. Virchows Arch: Int J Pathol. 2006;448(3):277–87. doi:10.1007/s00428-005-0118-9.CrossRef

22.

Li SL, Gao DL, Zhao ZH, Liu ZW, Zhao QM, Yu JX, et al. Correlation of matrix metalloproteinase suppressor genes RECK, VEGF, and CD105 with angiogenesis and biological behavior in esophageal squamous cell carcinoma. WJG. 2007;13(45):6076–81.PubMedCrossRef

23.

Sung CO, Park CK, Kim SH. Classification of epithelial-mesenchymal transition phenotypes in esophageal squamous cell carcinoma is strongly associated with patient prognosis. Mod Pathol: Off J U. S. Can Acad Pathol, Inc. 2011;24(8):1060–8. doi:10.1038/modpathol.2011.59.CrossRef

24.

Barbera MJ, Puig I, Dominguez D, Julien-Grille S, Guaita-Esteruelas S, Peiro S, et al. Regulation of Snail transcription during epithelial to mesenchymal transition of tumor cells. Oncogene. 2004;23(44):7345–54. doi:10.1038/sj.onc.1207990.PubMedCrossRef

25.

Guo HM, Zhang XQ, Xu CH, Zou XP. Inhibition of invasion and metastasis of gastric cancer cells through snail targeting artificial microRNA interference. Asian Pac J Cancer Prev: APJCP. 2011;12(12):3433–8.PubMed

26.

Castro Alves C, Rosivatz E, Schott C, Hollweck R, Becker I, Sarbia M, et al. Slug is overexpressed in gastric carcinomas and may act synergistically with SIP1 and Snail in the down-regulation of E-cadherin. J Pathol. 2007;211(5):507–15. doi:10.1002/path.2138.PubMedCrossRef

27.

Sawada K, Mitra AK, Radjabi AR, Bhaskar V, Kistner EO, Tretiakova M, et al. Loss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target. Cancer Res. 2008;68(7):2329–39. doi:10.1158/0008-5472.CAN-07-5167.PubMedCentralPubMedCrossRef

28.

Olmeda D, Jorda M, Peinado H, Fabra A, Cano A. Snail silencing effectively suppresses tumour growth and invasiveness. Oncogene. 2007;26(13):1862–74. doi:10.1038/sj.onc.1209997.PubMedCrossRef

29.

Roy HK, Iversen P, Hart J, Liu Y, Koetsier JL, Kim Y, et al. Down-regulation of SNAIL suppresses MIN mouse tumorigenesis: modulation of apoptosis, proliferation, and fractal dimension. Mol Cancer Ther. 2004;3(9):1159–65.PubMed

Title: Snail1 correlates with patient outcomes in E-cadherin-preserved gastroesophageal junction adenocarcinoma
Authors: H. Dong
L. Xie
C. Tang
S. Chen
Q. Liu
Q. Zhang
W. Zheng
Z. Zheng
H. Zhang
Publication date: 01-09-2014
Publisher: Springer Milan
Published in: Clinical and Translational Oncology / Issue 9/2014
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-013-1149-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 9/2014

Characterization of mechanism involved in acquired resistance to sorafenib in a mouse renal cell cancer RenCa model

Diagnostic performance of PET/CT with tracers other than F-18-FDG in oncology: an evidence-based review

Cell origins and significance of IL-17 in malignant pleural effusion

Overview of a chemoresponse assay in ovarian cancer

Effects of common polymorphisms rs2910164 in miR-146a and rs11614913 in miR-196a2 on susceptibility to colorectal cancer: a systematic review meta-analysis

Expression of Wilms’ tumor gene (WT1) is associated with survival in malignant pleural mesothelioma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer